Submit your email to push it up the queue
Invivo Research Inc., often referred to as Invivo, is a leading provider of preclinical research services headquartered in the United States. Founded in 2001, the company has established itself as a key player in the biotechnology and pharmaceutical industries, specialising in in vivo models and advanced imaging technologies. With operational facilities across North America and Europe, Invivo offers a range of core services, including pharmacology, toxicology, and efficacy studies, which are distinguished by their commitment to scientific excellence and innovation. The company has achieved notable milestones, such as the development of proprietary imaging techniques that enhance the accuracy of preclinical assessments. Recognised for its expertise and reliability, Invivo Research Inc. continues to support the advancement of drug development, positioning itself as a trusted partner for clients seeking to navigate the complexities of biomedical research.
How does Invivo Research Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Invivo Research Inc.'s score of 89 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Invivo Research Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Koninklijke Philips N.V., which means that any climate commitments or emissions data may be inherited from its parent organisation. As part of its corporate family relationship with Koninklijke Philips N.V., Invivo Research Inc. aligns with various sustainability initiatives, including those set forth by the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative. However, specific reduction targets or achievements for Invivo Research Inc. have not been disclosed. The lack of direct emissions data suggests that Invivo Research Inc. is in the early stages of establishing its own climate commitments, potentially relying on the broader sustainability framework and targets set by Koninklijke Philips N.V. As the company progresses, it may adopt more specific measures to address its carbon footprint and contribute to global climate goals.
Access structured emissions data, company-specific emission factors, and source documents
2007 | 2008 | 2009 | 2010 | 2014 | 2015 | 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 449,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 717,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 3 | 991,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Invivo Research Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.